GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Accounts Payable

Kyverna Therapeutics (Kyverna Therapeutics) Accounts Payable : $7.45 Mil (As of Mar. 2024)


View and export this data going back to 2024. Start your Free Trial

What is Kyverna Therapeutics Accounts Payable?

Kyverna Therapeutics's Accounts Payable for the quarter that ended in Mar. 2024 was $7.45 Mil.

Kyverna Therapeutics's quarterly Accounts Payable increased from Sep. 2023 ($3.02 Mil) to Dec. 2023 ($4.36 Mil) and increased from Dec. 2023 ($4.36 Mil) to Mar. 2024 ($7.45 Mil).

Kyverna Therapeutics's annual Accounts Payable increased from Dec. 2021 ($0.77 Mil) to Dec. 2022 ($1.45 Mil) and increased from Dec. 2022 ($1.45 Mil) to Dec. 2023 ($4.36 Mil).

Kyverna Therapeutics Accounts Payable Historical Data

The historical data trend for Kyverna Therapeutics's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kyverna Therapeutics Accounts Payable Chart

Kyverna Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
Accounts Payable
0.77 1.45 4.36

Kyverna Therapeutics Quarterly Data
Dec21 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Accounts Payable Get a 7-Day Free Trial 1.45 - 3.02 4.36 7.45

Kyverna Therapeutics Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Kyverna Therapeutics Accounts Payable Related Terms

Thank you for viewing the detailed overview of Kyverna Therapeutics's Accounts Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Kyverna Therapeutics (Kyverna Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kyverna Therapeutics Inc (NAS:KYTX) » Definitions » Accounts Payable
Comparable Companies
Traded in Other Exchanges
N/A
Address
5980 Horton Street, STE 550, Emeryville, CA, USA, 94608
Website
https://www.kyvernatx.com
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR.

Kyverna Therapeutics (Kyverna Therapeutics) Headlines

From GuruFocus

Kyverna Therapeutics Announces Pricing of Upsized Initial Public Offering

By PRNewswire • 02-12-2024